The estimated Net Worth of William D. Turner is at least $349 mil dollars as of 5 April 2022. Mr. Turner owns over 6,447 units of Sierra Oncology Inc stock worth over $349,022 and over the last 4 years he sold SRRA stock worth over $0. In addition, he makes $0 as Chief Regulatory and Technical Operations Officer at Sierra Oncology Inc.
William has made over 5 trades of the Sierra Oncology Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 6,447 units of SRRA stock worth $77,686 on 5 April 2022.
The largest trade he's ever made was exercising 10,000 units of Sierra Oncology Inc stock on 7 February 2022 worth over $120,500. On average, William trades about 2,500 units every 7 days since 2020. As of 5 April 2022 he still owns at least 6,347 units of Sierra Oncology Inc stock.
You can see the complete history of Mr. Turner stock trades at the bottom of the page.
William D. Turner serves as Chief Regulatory and Technical Operations Officer of the Company. Mr. William Turner has more than 25 years of drug development and drug commercialization experience, leading organizations through all phases of product development including commercial drug process, method and facility validations, all phases of clinical programs, numerous drug application filings and several global approvals. William was Senior Vice President of Technical Operations and Regulatory Science at Aimmune Therapeutics for several years. Prior to that, he served as Vice President of Regulatory Affairs and Global Quality at Dynavax Technologies Corporation as well as several years in a leadership position at MedImmune (now AstraZeneca). He has significant experience in both small molecule and biologic development and has led teams in many therapeutic areas including vaccinology, oncology, hematology, allergy and respiratory. Mr. Turner holds a degree in Medical Microbiology with a minor in Chemistry from California State University at Long Beach .
William's mailing address filed with the SEC is C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DR., SUITE 110, SAN MATEO, CA, 94404.
Over the last 8 years, insiders at Sierra Oncology Inc have traded over $0 worth of Sierra Oncology Inc stock and bought 8,528,701 units worth $69,515,388 . The most active insiders traders include Andrew Sinclair, Llp Abingworth, eJames N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of $21,400,348. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth $77,686.
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
Sierra Oncology Inc executives and other stock owners filed with the SEC include: